There is an important distinction between a treatment being cost-effective and it being affordable for the NHS as illustrated by the example of tirzepatide. NICE has concluded that tirzepatide is cost-effective in appropriately selected patients because of the health gains it delivers through reductions in obesity-related disease and its complications. However, the overall budget impact is a separate question. When millions of people could potentially be eligible for treatment, even a cost-effective intervention can create major financial pressures for the NHS. We are still at a relatively early stage of implementation, yet tirzepatide has already become one of the NHS's highest-cost medicines. If access expands in line with NICE guidance over the coming years, expenditure will increase substantially unless drug prices fall significantly, prescribing criteria change or treatment strategies evolve. Another important issue is that we still have key unanswered questions about long-ter...
Updates from Imperial College London's Professor of Primary Care & Public Health